Osteoporosis drug studied for spine surgery recovery – but trial pulled

NCT ID NCT06973109

Terminated Disease control Sponsor: University of Pittsburgh Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if romosozumab (Evenity) could improve bone density and muscle mass in postmenopausal women with osteoporosis undergoing lumbar spine surgery. Participants would have received monthly injections of romosozumab or weekly alendronate pills for 12 months. However, the trial was withdrawn before any volunteers enrolled, so no data were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Romosozumab (Evenity)
What this could lead to: If it worked, romosozumab could improve bone density and muscle mass, potentially reducing complications and aiding recovery after spine surgery in women with osteoporosis.
What could go wrong: The trial was withdrawn before enrolling any participants, so no results are available. Even if conducted, it was a small Phase 2 study, and benefits may not be confirmed in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS, POST-MENOPAUSAL

Contacts and locations

Locations

University of Pittsburgh Medical Center (UPMC) - Presbyterian Hospital

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.